HK1215247A1 - 作為 拮抗劑的吡唑化合物 - Google Patents

作為 拮抗劑的吡唑化合物

Info

Publication number
HK1215247A1
HK1215247A1 HK16103130.7A HK16103130A HK1215247A1 HK 1215247 A1 HK1215247 A1 HK 1215247A1 HK 16103130 A HK16103130 A HK 16103130A HK 1215247 A1 HK1215247 A1 HK 1215247A1
Authority
HK
Hong Kong
Prior art keywords
crth2
pyrazole compounds
antagonists
pyrazole
compounds
Prior art date
Application number
HK16103130.7A
Other languages
English (en)
Inventor
‧安德斯克維茲
‧馬蒂雷斯
‧奧斯特
‧里斯特
‧希瑟
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43799503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1215247(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of HK1215247A1 publication Critical patent/HK1215247A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK16103130.7A 2011-01-24 2013-12-10 作為 拮抗劑的吡唑化合物 HK1215247A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11151876 2011-01-24

Publications (1)

Publication Number Publication Date
HK1215247A1 true HK1215247A1 (zh) 2016-08-19

Family

ID=43799503

Family Applications (3)

Application Number Title Priority Date Filing Date
HK16103130.7A HK1215247A1 (zh) 2011-01-24 2013-12-10 作為 拮抗劑的吡唑化合物
HK15111230.0A HK1210467A1 (zh) 2011-01-24 2013-12-10 作為 拮抗劑的吡唑化合物
HK13113692.9A HK1186183A1 (zh) 2011-01-24 2013-12-10 作為 拮抗劑的吡唑化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK15111230.0A HK1210467A1 (zh) 2011-01-24 2013-12-10 作為 拮抗劑的吡唑化合物
HK13113692.9A HK1186183A1 (zh) 2011-01-24 2013-12-10 作為 拮抗劑的吡唑化合物

Country Status (36)

Country Link
US (1) US8759386B2 (zh)
EP (1) EP2668181B1 (zh)
JP (1) JP5695216B2 (zh)
KR (2) KR101923365B1 (zh)
CN (4) CN104628705B (zh)
AP (1) AP3343A (zh)
AR (1) AR084916A1 (zh)
AU (1) AU2012210718B2 (zh)
BR (1) BR112013017570B1 (zh)
CA (1) CA2825458C (zh)
CL (1) CL2013001945A1 (zh)
CO (1) CO6801731A2 (zh)
CY (1) CY1116012T1 (zh)
DK (1) DK2668181T3 (zh)
EA (1) EA022559B1 (zh)
EC (1) ECSP13012832A (zh)
ES (1) ES2529452T3 (zh)
GE (1) GEP20156332B (zh)
HK (3) HK1215247A1 (zh)
HR (1) HRP20150069T1 (zh)
IL (1) IL226920A (zh)
MA (1) MA34838B1 (zh)
MX (1) MX342830B (zh)
MY (1) MY163012A (zh)
PE (1) PE20140860A1 (zh)
PH (1) PH12018501531A1 (zh)
PL (1) PL2668181T3 (zh)
PT (1) PT2668181E (zh)
RS (1) RS53785B1 (zh)
SG (1) SG192096A1 (zh)
SI (1) SI2668181T1 (zh)
TN (1) TN2013000280A1 (zh)
TW (1) TWI527809B (zh)
UA (1) UA109696C2 (zh)
UY (1) UY33873A (zh)
WO (1) WO2012101043A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI527809B (zh) * 2011-01-24 2016-04-01 百靈佳殷格翰國際股份有限公司 作為ｃｒｔｈ２拮抗劑之吡唑化合物
WO2012130633A1 (en) * 2011-03-25 2012-10-04 Boehringer Ingelheim International Gmbh Pyrazole compounds as crth2 antagonists
US20140148492A1 (en) * 2012-11-23 2014-05-29 Boehringer Ingelheim International Gmbh Bicyclosubstituted pyrazole compounds for treating hair loss
WO2014079805A1 (en) * 2012-11-23 2014-05-30 Boehringer Ingelheim International Gmbh Pyrazole compounds for treating hairloss
BR112020019128A2 (pt) * 2018-03-23 2021-01-12 Palatin Technologies, Inc. Formulação farmacêutica de liberação em trato gastrointestinal inferior; formulação farmacêutica de liberação no trato gastrointestinal inferior preparada por um processo; processo; formulação de liberação modificada; composição farmacêutica adequada para administração oral para tratamento de uma doença inflamatória intestinal; e método de tratamento de doença inflamatória intestinal (ibd) em um paciente humano com ibd
WO2020132384A1 (en) 2018-12-21 2020-06-25 Celgene Corporation Thienopyridine inhibitors of ripk2

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
PL356487A1 (en) * 1999-11-10 2004-06-28 Takeda Chemical Industries, Ltd. 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
EP1471057B1 (en) 2003-04-25 2006-01-18 Actimis Pharmaceuticals, Inc. Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2
DE602004011966T2 (de) * 2003-10-24 2009-02-12 Glaxo Group Ltd., Greenford Heterocyclylverbindungen
CN101084209A (zh) * 2004-12-21 2007-12-05 德福根有限公司 具有Kv4离子通道活性的化合物
JP4950542B2 (ja) * 2006-04-07 2012-06-13 岩手東芝エレクトロニクス株式会社 固体撮像装置およびその製造方法
ATE489088T1 (de) 2006-06-06 2010-12-15 Glaxo Group Ltd N- (phenylmethyl) -2- (1h-pyrazol-4-yl) acetamid- derivate als p2x7-antagonisten zur behandlung von schmerzen, entzündungen und neurodegeneration
WO2008065493A1 (en) * 2006-11-27 2008-06-05 Pfizer Products Inc. Pyrazole analogs
WO2009042138A1 (en) 2007-09-25 2009-04-02 Actimis Pharmaceuticals, Inc. Alkylthio pyrimidines as crth2 antagonists
CL2008002827A1 (es) * 2007-09-25 2009-11-27 Actimis Pharmaceuticals Inc Compuestos derivados de 2-s-bencil pirimidina, antagonistas del receptor crth2; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades alergicas mediadas por eosinofilos y basofilos, tales como asma, rinitis alergica, dermatitis atopica, conjuntivitis alergica, sinusitis y psoriasis, entre otras
JP2011088826A (ja) * 2008-01-31 2011-05-06 Astellas Pharma Inc 芳香族カルボン酸化合物
UY31956A (es) * 2008-07-03 2010-01-29 Amira Pharmaceuticals Inc Antagonistas de heteroalquilo de receptores de prostaglandina d2
GB2463788B (en) * 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010057118A2 (en) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors
US20120129820A1 (en) * 2009-02-09 2012-05-24 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
CN108383789A (zh) * 2010-01-27 2018-08-10 艾克提麦斯医药品有限公司 作为crth2拮抗剂的吡唑化合物
EP2598145A1 (en) * 2010-07-28 2013-06-05 Boehringer Ingelheim International GmbH Pharmaceutical composition for treatment of respiratory and inflammatory diseases
TWI527809B (zh) * 2011-01-24 2016-04-01 百靈佳殷格翰國際股份有限公司 作為ｃｒｔｈ２拮抗劑之吡唑化合物

Also Published As

Publication number Publication date
AP3343A (en) 2015-07-31
HK1186183A1 (zh) 2014-03-07
CN104961732A (zh) 2015-10-07
PH12018501531A1 (en) 2019-04-08
CA2825458A1 (en) 2012-08-02
AR084916A1 (es) 2013-07-10
IL226920A (en) 2016-11-30
UY33873A (es) 2012-07-31
MA34838B1 (fr) 2014-01-02
AP2013006942A0 (en) 2013-06-30
BR112013017570A2 (pt) 2016-10-18
HK1210467A1 (zh) 2016-04-22
WO2012101043A1 (en) 2012-08-02
CO6801731A2 (es) 2013-11-29
UA109696C2 (xx) 2015-09-25
TWI527809B (zh) 2016-04-01
MX342830B (es) 2016-10-14
DK2668181T3 (da) 2015-01-19
PE20140860A1 (es) 2014-07-20
HRP20150069T1 (hr) 2015-02-27
MX2013008082A (es) 2013-09-13
PT2668181E (pt) 2015-02-05
PL2668181T3 (pl) 2015-04-30
ECSP13012832A (es) 2013-09-30
CN104961732B (zh) 2017-07-11
TW201245184A (en) 2012-11-16
CA2825458C (en) 2021-01-26
SG192096A1 (en) 2013-08-30
CN104628705B (zh) 2017-04-12
CN107011332A (zh) 2017-08-04
EA201300857A1 (ru) 2013-12-30
CN107011332B (zh) 2020-03-13
KR102251939B1 (ko) 2021-05-14
US20130023576A1 (en) 2013-01-24
EA022559B1 (ru) 2016-01-29
US8759386B2 (en) 2014-06-24
CY1116012T1 (el) 2017-01-25
TN2013000280A1 (en) 2014-11-10
AU2012210718B2 (en) 2016-06-02
CL2013001945A1 (es) 2013-10-25
JP5695216B2 (ja) 2015-04-01
JP2014502986A (ja) 2014-02-06
CN103339125B (zh) 2015-07-15
EP2668181B1 (en) 2014-11-05
ES2529452T3 (es) 2015-02-20
BR112013017570B1 (pt) 2022-01-11
AU2012210718A1 (en) 2013-07-04
CN103339125A (zh) 2013-10-02
RS53785B1 (en) 2015-06-30
CN104628705A (zh) 2015-05-20
EP2668181A1 (en) 2013-12-04
KR20140005931A (ko) 2014-01-15
NZ611695A (en) 2015-04-24
KR101923365B1 (ko) 2018-11-30
GEP20156332B (en) 2015-07-27
SI2668181T1 (sl) 2015-02-27
KR20180129962A (ko) 2018-12-05
MY163012A (en) 2017-07-31

Similar Documents

Publication Publication Date Title
IL286152A (en) Modified imidazopyridinyl-aminopyridine compounds
AP3360A (en) Pyrazole compounds as CRTH2 antagonists
EP2627178A4 (en) QUINAZOLINONE-LIKE COMPOUNDS AS CRTH2 ANTAGONISTS
AP3391A (en) 2-Amino-4-arylthiazole compounds as TROA1 antagonists
EP2698368A4 (en) NEW PYRAZOLE DERIVATIVE
EP2738170A4 (en) HETEROCYCLIC COMPOUND
GB201118652D0 (en) New compounds
GB201118654D0 (en) New compounds
GB201118675D0 (en) New compounds
EP2709609A4 (en) HETEROCYCLIC COMPOUNDS
HK1191862A1 (zh) 吡唑衍生物
GB201106814D0 (en) New compounds
HK1186183A1 (zh) 作為 拮抗劑的吡唑化合物
EP2771012A4 (en) NEW CONNECTIONS
ZA201303800B (en) Pyrazole compounds
HK1191946A1 (zh) 新型六氫吡咯並咪唑酮化合物
GB201119590D0 (en) New compounds I
GB201102024D0 (en) Novel heterocyclic compounds 3
GB201101822D0 (en) Novel heterocyclic compounds 2
GB201101823D0 (en) Novel heterocyclic compounds 4
GB201101821D0 (en) Novel heterocyclic compounds 1

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230116